EXEL Exelixis Inc

Price (delayed)

$20.695

Market cap

$6.52B

P/E Ratio

66.76

Dividend/share

N/A

EPS

$0.31

Enterprise value

$6.08B

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work ...

Highlights
The revenue has grown by 16% YoY and by 12% from the previous quarter
The gross profit has grown by 15% YoY and by 12% from the previous quarter
The company's net income has shrunk by 67% YoY but it rose by 45% QoQ
The company's EPS has shrunk by 66% YoY but it rose by 41% QoQ
EXEL's quick ratio is down by 36% year-on-year and by 7% since the previous quarter
The debt has increased by 10% YoY

Key stats

What are the main financial stats of EXEL
Market
Shares outstanding
315.05M
Market cap
$6.52B
Enterprise value
$6.08B
Valuations
Price to earnings (P/E)
66.76
Price to book (P/B)
3.17
Price to sales (P/S)
5.62
EV/EBIT
53.82
EV/EBITDA
46.89
EV/Sales
5.26
Earnings
Revenue
$1.16B
EBIT
$112.98M
EBITDA
$129.67M
Free cash flow
$218.09M
Per share
EPS
$0.31
Free cash flow per share
$0.69
Book value per share
$6.52
Revenue per share
$3.68
TBVPS
$7.33
Balance sheet
Total assets
$2.37B
Total liabilities
$324.19M
Debt
$53.22M
Equity
$2.04B
Working capital
$1.34B
Liquidity
Debt to equity
0.03
Current ratio
6.24
Quick ratio
5.95
Net debt/EBITDA
-3.39
Margins
EBITDA margin
11.2%
Gross margin
96%
Net margin
8.1%
Operating margin
8.7%
Efficiency
Return on assets
4.3%
Return on equity
4.9%
Return on invested capital
7.1%
Return on capital employed
5.3%
Return on sales
9.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
1.7%
1 week
4.41%
1 month
6.51%
1 year
-13.19%
YTD
3.11%
QTD
13.58%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$1.16B
Gross profit
$1.11B
Operating income
$100.12M
Net income
$94.04M
Gross margin
96%
Net margin
8.1%
Exelixis's operating income has surged by 90% QoQ but it has shrunk by 69% YoY
EXEL's operating margin has dropped by 73% year-on-year but it has surged by 71% since the previous quarter
The net margin has plunged by 71% YoY but it has increased by 29% from the previous quarter
The company's net income has shrunk by 67% YoY but it rose by 45% QoQ

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
P/E
66.76
P/B
3.17
P/S
5.62
EV/EBIT
53.82
EV/EBITDA
46.89
EV/Sales
5.26
The company's EPS has shrunk by 66% YoY but it rose by 41% QoQ
The P/E is 13% below the 5-year quarterly average of 75.1
EXEL's P/B is 83% below its 5-year quarterly average of 18.4 and 11% below its last 4 quarters average of 3.5
The company's equity rose by 11% YoY and by 7% QoQ
EXEL's price to sales (P/S) is 52% lower than its 5-year quarterly average of 11.5 and 15% lower than its last 4 quarters average of 6.5
The revenue has grown by 16% YoY and by 12% from the previous quarter

Efficiency

How efficient is Exelixis business performance
The company's return on sales has shrunk by 72% YoY but it rose by 46% QoQ
The ROA has plunged by 71% YoY but it has grown by 39% from the previous quarter
The ROIC has plunged by 71% YoY but it has soared by 58% from the previous quarter
The company's return on equity has shrunk by 70% YoY but it rose by 40% QoQ

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's total liabilities has surged by 52% year-on-year and by 16% since the previous quarter
EXEL's current ratio is down by 36% year-on-year and by 7% since the previous quarter
The debt is 97% less than the equity
The company's equity rose by 11% YoY and by 7% QoQ
The debt has increased by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.